secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001437749-24-036247
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic receives $3.1M Gates Foundation grant for RSV and malaria mAb development
--------------------------------------------------------------------------------

- Grant of $3,092,136 from Bill & Melinda Gates Foundation for monoclonal antibody development using C1 platform.
- Targets RSV (100K+ deaths annually, 99% in LMICs) and malaria (249M cases, 608K deaths in 2022).
- Aims to reduce production costs and improve global access to affordable therapeutics for underserved populations.
- Dyadic plans to commercialize resulting antibodies via licensure if development succeeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924036247/0001437749-24-036247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924036247/dyai20241120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer